699 results found

Using the same invalidity evidence to address apparatus and corresponding method claims in inter partes review ("IPR") petitions can present difficulties depending on the claim language used in the apparatus claims.

On May 19, 2022, ALJ MaryJoan McNamara issued the public version of her March 25, 2022 initial determination.

The Board of Trustees of the Leland Stanford Junior University ("Stanford") appeals the final rejection of patent claims in its patent Application No. 13/486,982.

On July 13, 2018, the Federal Circuit issued an opinion in Polara Engineering v. Campbell Company, which has been noticed for its discussion of enhanced damages.

The Federal Circuit has launched an assault on common claiming techniques in pharma and chemical patents.

As a follow-up to the previous post on AI Initiatives at the EPO, we provide an update on the activities by the JPO – 1) creation of a new Team for Supporting AI Examinations in January 2021...

In the appeal of USSN 17/963,407 (Appeal 2025-001881) to the Patent Trial and Appeal Board (PTAB), a finding of obviousness by Primary Examiner Drew Becker...

Claim 25 of Application No. 12/393,833, continued from the '803 application, also recited using random MPS to determine fetal aneuploidy.

The U.S. Patent and Trademark Office (USPTO) issued a final rule in the Federal Register on November 16, 2023, to create a separate design patent practitioner bar for practice in design patent proceedings only.

On June 27, 2024, the United States Patent and Trade Office ("USPTO") published a request for comments ("RFC") in the Federal Register inquiring about the current state of the experimental use defense.

Following Ed Garlepp's great discussion on AI disclosure issues[1][2], I want to describe a related problem with AI and issues arising under the written description requirement that I often bring up when presenting on this topic.

The first was issued in United Cannabis Corporation v. Pure Hemp Collective Inc., No. 2022-1363 (May 8, 2023) (Lourie, Cunningham and Stark*), which involved an appeal of a denial of a motion for...

In Maquet Cardiovascular LLC. v. Abiomed Inc., Appeal No. 2023-2045, March 21, 2025, the Federal Circuit provided guidance as to when the prosecution history of one member of a patent family may act as an estoppel...

Last month, the Federal Circuit issued a non-precedential decision affirming the PTAB's holdings in two final written decisions. P Tech, LLC (herein "P Tech") appealed the PTAB decisions...

Okay, let's get this out of the way up front. The answer is maybe… but only with a lot more work and with substantially reduced claim scope.

On October 19, 2022, the Patent Trial and Appeal Board (PTAB) overturned the obviousness rejection of a claim to an aqueous dispersion.

Amneal Pharmaceuticals, LLC. filed two petitions for inter partes review of claims 1–13 and 16–19 of U.S. Patent No. 9,034,376 of Purdue Pharma L.P., P.F. Laboratories, Inc. and Purdue Pharmaceuticals L.P.